CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT

Bone Marrow Transplantation
M KappG U Grigoleit

Abstract

The GVL effect following allo-SCT is one of the most prominent examples showing the ability of the immune system to eliminate malignant hematological diseases. Tumor-associated Ags (TAA), for instance WT1 and proteinase-3, have been proposed as targets for T cells to establish a GVL effect. Here, we examined an additional TAA (MUC1) as a possible T-cell target of GVL-related immune responses. We have defined new peptide epitopes from the MUC1 Ag to broaden patients' screening and to expand the repertoire of immunologic monitoring as well as for therapeutic approaches in the future. Twenty-eight patients after allo-SCT have been screened for T-cell responses toward TAA (proteinase-3, WT1, MUC1). We could detect a significant relationship between relapse and the absence of a TAA-specific T-cell response, whereby only 2/13 (15%) patients with TAA-specific CTL relapsed, in contrast to 9/15 (60%) patients without TAA-specific CTL responses (P<0.05). In conclusion, CD8(+) T-cell responses directed to TAA might contribute to the GVL effect. These observations highlight both the importance and the potential of immunotherapeutic approaches after allo-SCT.

References

Jun 15, 1989·International Journal of Cancer. Journal International Du Cancer·A GirlingJ Taylor-Papadimitriou
Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·B D WalkerR T Schooley
Mar 15, 1994·Proceedings of the National Academy of Sciences of the United States of America·E CelisH M Serra
Mar 19, 1996·Proceedings of the National Academy of Sciences of the United States of America·L J Zhou, T F Tedder
May 29, 1998·The Journal of Clinical Investigation·P YotndaP Langlade-Demoyen
Dec 22, 1999·Immunogenetics·H RammenseeS Stevanović
May 18, 2001·Nature·F R Appelbaum
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ashraf BadrosGuido Tricot
Mar 29, 2002·International Journal of Cancer. Journal International Du Cancer·Carmen ScheibenbogenDirk Schadendorf
Jul 3, 2002·Nature Reviews. Cancer·Stefan Stevanovic
Jan 31, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ryotaro NakamuraA John Barrett
Sep 15, 2004·Proceedings of the National Academy of Sciences of the United States of America·Yoshihiro OkaHaruo Sugiyama
Dec 24, 2005·Journal of Cancer Research and Clinical Oncology·Brigitte GückelDiethelm Wallwiener
May 30, 2006·Advances in Immunology·Catherine J Wu, Jerome Ritz

❮ Previous
Next ❯

Citations

Mar 24, 2012·Cancer Immunology, Immunotherapy : CII·Corey M MungerShantaram S Joshi
Jan 10, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Monica CasucciChiara Bonini
Apr 17, 2010·Japanese Journal of Clinical Oncology·Haruo Sugiyama
Jul 10, 2009·Current Opinion in Hematology·Markus KappGötz Ulrich Grigoleit
Jul 20, 2010·Immunotherapy·David S RitchiePaul Neeson
Aug 21, 2013·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Masahiro Ogasawara
Feb 17, 2011·Expert Review of Hematology·Gheath Alatrash, Jeffrey J Molldrem
Sep 9, 2009·British Journal of Haematology·Olle RingdénMichael Uhlin
Apr 1, 2015·Journal of Immunological Methods·Gorm Thorlacius-UssingAnders Elm Pedersen
Mar 13, 2012·Cellular Immunology·Bangqing YuanGang Zhao
Mar 24, 2010·Pediatric Clinics of North America·Terry J FryPeter Bader
Jul 15, 2015·Oncoimmunology·Simone KayserTobias Feuchtinger
Mar 26, 2013·Oncoimmunology·Sylvia SnauwaertTessa Kerre
Aug 11, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henk LokhorstUNKNOWN International Myeloma Working Group
Oct 31, 2017·Annals of Hematology·Dan YangYanli Xu
Mar 13, 2017·Current Hematologic Malignancy Reports·Qaiser Bashir, Muzaffar H Qazilbash
Oct 7, 2015·Cancer Immunology, Immunotherapy : CII·Susanne HofmannBarbara-Ann Guinn
Jun 11, 2021·Current Treatment Options in Oncology·Panayotis Kaloyannidis, John Apostolidis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.